Dr. Philip Strandwitz is a specialist in the microbiome, with a focus on the gut-brain-axis. Philip received his PhD in Biology under the guidance of Dr. Kim Lewis at Northeastern University, where he focused on cultivating unique bacteria from the human gut microbiota, as well as studying their ability to modulate neurotransmitters. He has since assembled a broad range of clinical and academic collaborators to further profile the link between the human microbiome and the gut-brain-axis. Philip has presented at numerous conferences, including those held by the New York Academy of Science, Keystone Symposia, and the American Society of Microbiology. He is now CEO as Holobiome, a company he co-founded to translate microbiome science into novel therapeutics to treat diseases of the central and enteric nervous systems. Holobiome announced an early stage research collaboration with Johnson & Johnson Innovation LLC, Johnson & Johnson Consumer Inc. and Janssen Research & Development, LLC in early 2018, and is currently sponsored by Amgen for wet lab space at LabCentral in Cambridge, MA.